Asian Journal of Advances in Research

Antimicrobial de-escalation is a central but incompletely resolved component of hospital antimicrobial stewardship. It seeks to reduce unnecessary breadth of antibacterial treatment after initial empirical therapy by discontinuing redundant agents, replacing broad-spectrum drugs with narrower alternatives, or stopping therapy when bacterial infection becomes unlikely. The clinical logic is compelling: early adequate therapy remains essential in severe infection, yet continued broad-spectrum exposure contributes to adverse drug events, ecological disruption and selection pressure. The evidence base, however, is methodologically uneven. Observational studies repeatedly associate de-escalation with equal or better clinical outcomes, but the decision to de-escalate is strongly influenced by improving physiology, microbiological documentation and lower perceived risk, creating substantial confounding by indication and clinical trajectory. Randomised evidence is limited and does not establish a mortality benefit. Recent multicentre cohorts, target-trial emulations and pragmatic stewardship trials strengthen the safety case for de-escalation in selected patients with sepsis, including many with negative cultures, while also demonstrating large inter-hospital variation and persistent behavioural barriers. Diagnostic innovations can accelerate actionable information, but rapid organism identification, susceptibility testing or methicillin-resistant Staphylococcus aureus screening do not automatically reduce broad-spectrum exposure unless embedded within stewardship workflows. Evidence that de-escalation itself prevents antimicrobial resistance remains notably weaker than evidence that it reduces exposure to selected broad-spectrum agents. This critical narrative review synthesises clinical effectiveness, measurement approaches, diagnostic enablers, implementation barriers and ecological uncertainties across acute hospital practice. It argues that de-escalation should be understood as a structured reassessment process rather than a single drug-switch event, with decisions anchored to adequacy of initial therapy, source control, evolving infection probability, microbiological data, host risk and clinical trajectory. Priority research should standardise exposure definitions, use causal designs that address time-varying confounding, measure ecological as well as patient-centred outcomes, and test diagnostic-stewardship interventions in diverse healthcare settings.